Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

Core Insights - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][3] Company Overview - Pharvaris aims to provide injectable-like efficacy and placebo-like tolerability with the convenience of oral therapies for the prevention and treatment of bradykinin-mediated angioedema attacks [3] - The company is currently evaluating the efficacy and safety of its lead candidate, deucrictibant, in pivotal Phase 3 studies for both prophylaxis and on-demand treatment of HAE attacks [3] Upcoming Presentations - Pharvaris announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit, scheduled for July 10-13, 2025, in Baltimore, Maryland [1] - Multiple poster presentations will be held on July 11, 2025, featuring various studies related to deucrictibant, including long-term safety and efficacy, disease control, and health-related quality of life improvements in HAE patients [2][4]